Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Khsheibun, Rana ^a   Paperna, Tamar ^a   Volkowich, Anat ^b   Lejbkowicz, Izabella ^a   Avidan, Nili ^a   Miller, Ariel ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN TYROSINE KINASE; BETA INTERFERON;

ADOLESCENT; ADULT; AGED; ANTIBODY LABELING; ARTICLE; BAD GENE; CANCER GRADING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MALE; MICROARRAY ANALYSIS; MYOCD GENE; ONCOGENE; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SENSITIVITY AND SPECIFICITY; SRC GENE; SRF GENE; TISSUE MICROARRAY; TUMOR VOLUME; UNDIFFERENTIATED PLEOMORPHIC SARCOMA; VALIDATION PROCESS; VERY ELDERLY; B LYMPHOCYTE; EPSTEIN BARR VIRUS; GENETICS; LYMPHOCYTE SUBPOPULATION; METABOLISM; MULTIPLE SCLEROSIS; PHYSIOLOGY; TRANSFORMED CELL LINE;

B-LYMPHOCYTES; CELL LINE, TRANSFORMED; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON-BETA; LYMPHOCYTE SUBSETS; MULTIPLE SCLEROSIS;

EID: 84904248557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102331     Document Type: Article

References (77)

1. von Budingen HC, Bar-Or A, Zamvil SS (2011) B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 23: 713-720.
2. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV (2012) The evidence for a role of B cells in multiple sclerosis. Neurology 78: 823-832.
3. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8: 613-623.
4. Casiraghi C, Shanina I, Cho S, Freeman ML, Blackman MA, et al. (2012) Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein- Barr virus and multiple sclerosis. PLoS Pathog 8: e1002715.
5. Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, et al. (2010) Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 69: 677-693.
6. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460-471.
7. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688. (Pubitemid 351240747)
8. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, et al. (2013) MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 210: 2921-2937.
9. Weber MS, Hemmer B, Cepok S (2011) The role of antibodies in multiple sclerosis. Biochim Biophys Acta 1812: 239-245.
10. Buck D, Hemmer B (2011) Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol 258: 1747-1762.
11. Miller A, Avidan N, Tzunz-Henig N, Glass-Marmor L, Lejbkowicz I, et al. (2008) Translation towards personalized medicine in Multiple Sclerosis. J Neurol Sci 274: 68-75.
12. Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, et al. (2011) Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS One 6: e29648.
13. Comabella M, Vandenbroeck K (2011) Pharmacogenomics and multiple sclerosis: moving toward individualized medicine. Curr Neurol Neurosci Rep 11: 484-491.
14. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, et al. (2009) A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132: 3353-3365.
15. van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, et al. (2010) Major Differences in the Responses of Primary Human Leukocyte Subsets to IFN-{beta}. J Immunol 185: 5888-5899.
16. Henig N, Avidan N, Mandel I, Staun-Ram E, Ginzburg E, et al. (2013) Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells. PLoS One 8: e62366.
17. Gonzalez-Navajas JM, Lee J, David M, Raz E (2012) Immunomodulatory functions of type I interferons. Nat Rev Immunol 12: 125-135.
18. Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, et al. (2003) Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci U S A 100: 13453-13458. (Pubitemid 37444763)
19. Green NM, Laws A, Kiefer K, Busconi L, Kim YM, et al. (2009) Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol 183: 1569-1576.
20. Poovassery JS, Bishop GA (2012) Type I IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms. J Immunol 189: 1757-1764.
21. Walsh ER, Pisitkun P, Voynova E, Deane JA, Scott BL, et al. (2012) Dual signaling by innate and adaptive immune receptors is required for TLR7- induced B-cell-mediated autoimmunity. Proc Natl Acad Sci U S A 109: 16276-16281.
22. Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, Kumpfel T, et al. (2008) Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455-1463. (Pubitemid 351806460)
23. Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, et al. (2011) B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J Immunol 186: 4518-4526.
24. Wroblewski JM, Copple A, Batson LP, Landers CD, Yannelli JR (2002) Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods 264: 19-28. (Pubitemid 34615887)
25. Sie L, Loong S, Tan EK (2009) Utility of lymphoblastoid cell lines. J Neurosci Res 87: 1953-1959.
26. Caliskan M, Cusanovich DA, Ober C, Gilad Y (2011) The effects of EBV transformation on gene expression levels and methylation profiles. Hum Mol Genet 20: 1643-1652.
27. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, et al. (2003) Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 33: 422-425. (Pubitemid 36278862)
28. Hu VW, Frank BC, Heine S, Lee NH, Quackenbush J (2006) Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes. BMC Genomics 7: 118.
29. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, et al. (2009) Pharmacogenomic discovery using cell-based models. Pharmacol Rev 61: 413-429.
30. Morag A, Kirchheiner J, Rehavi M, Gurwitz D (2010) Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics 11: 327-340.
31. Disanto G, Sandve GK, Berlanga-Taylor AJ, Morahan JM, Dobson R, et al. (2012) Genomic regions associated with multiple sclerosis are active in B cells. PLoS One 7: e32281.
32. Disanto G, Sandve GK, Berlanga-Taylor AJ, Ragnedda G, Morahan JM, et al. (2012) Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Hum Mol Genet 21: 3575-3586.
33. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127.
34. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231. (Pubitemid 13158528)
35. Lee JE, Nam HY, Shim SM, Bae GR, Han BG, et al. (2010) Expression phenotype changes of EBV-transformed lymphoblastoid cell lines during longterm subculture and its clinical significance. Cell Prolif 43: 378-384.
36. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J (2000) Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20: 857-866.
37. Khan OA, Dhib-Jalbut SS (1998) Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology 51: 738-742. (Pubitemid 28449252)
38. Mandel I, Paperna T, Glass-Marmor L, Volkowich A, Badarny S, et al. (2012) Tight junction proteins expression and modulation in immune cells and multiple sclerosis. J Cell Mol Med 16: 765-775.
39. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
40. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Roy Stat Soc B 57: 289-300.
41. Rusinova I, Forster S, Yu S, Kannan A, Masse M, et al. (2013) Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 41: D1040-1046.
42. Dorner M, Zucol F, Berger C, Byland R, Melroe GT, et al. (2008) Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin. J Virol 82: 4400-4412. (Pubitemid 351563676)
43. Monson NL (2008) The natural history of B cells. Curr Opin Neurol 21 Suppl 1: S3-8.
44. Ohtsuka T, Nakanishi H, Ikeda W, Satoh A, Momose Y, et al. (1998) Nexilin: a novel actin filament-binding protein localized at cell-matrix adherens junction. J Cell Biol 143: 1227-1238. (Pubitemid 28559824)
45. Spicer AP, Joo A, Bowling RA, Jr. (2003) A hyaluronan binding link protein gene family whose members are physically linked adjacent to chondroitin sulfate proteoglycan core protein genes: the missing links. J Biol Chem 278: 21083-21091. (Pubitemid 36806420)
46. Miyashita M, Oshiumi H, Matsumoto M, Seya T (2011) DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol Cell Biol 31: 3802-3819.
47. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
48. Durai R, Davies M, Yang W, Yang SY, Seifalian A, et al. (2006) Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol 28: 1317-1325.
49. Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K (2005) Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol 35: 2081-2088. (Pubitemid 41015047)
50. Sierro S, Romero P, Speiser DE (2011) The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 15: 91-101.
51. Batten M, Ramamoorthi N, Kljavin NM, Ma CS, Cox JH, et al. (2010) IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J Exp Med 207: 2895-2906.
52. Harker JA, Dolgoter A, Zuniga EI (2013) Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4(+) T cell responses and viral control during chronic infection. Immunity 39: 548-559.
53. Benschop RJ, Cambier JC (1999) B cell development: signal transduction by antigen receptors and their surrogates. Curr Opin Immunol 11: 143-151. (Pubitemid 29154898)
54. Chesik D, De Keyser J, Glazenburg L, Wilczak N (2006) Insulin-like growth factor binding proteins: regulation in chronic active plaques in multiple sclerosis and functional analysis of glial cells. Eur J Neurosci 24: 1645-1652. (Pubitemid 44427533)
55. Zhou R, Flaswinkel H, Schneider MR, Lahm H, Hoeflich A, et al. (2004) Insulin-like growth factor-binding protein-4 inhibits growth of the thymus in transgenic mice. J Mol Endocrinol 32: 349-364. (Pubitemid 38584641)
56. Winkelmann R, Sandrock L, Porstner M, Roth E, Mathews M, et al. (2011) B cell homeostasis and plasma cell homing controlled by Kruppel-like factor 2. Proc Natl Acad Sci U S A 108: 710-715.
57. Workman CJ, Vignali DA (2005) Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 174: 688-695. (Pubitemid 40094261)
58. Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, et al. (2011) PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med 208: 395-407.
59. von Budingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, et al. (2012) B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 122: 4533-4543.
60. Yoshimoto T, Okada K, Morishima N, Kamiya S, Owaki T, et al. (2004) Induction of IgG2a class switching in B cells by IL-27. J Immunol 173: 2479-2485. (Pubitemid 39063105)
61. Lappalainen T, Sammeth M, Friedlander MR, t Hoen PA, Monlong J, et al. (2013) Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501: 506-511.
62. Min JL, Taylor JM, Richards JB, Watts T, Pettersson FH, et al. (2011) The use of genome-wide eQTL associations in lymphoblastoid cell lines to identify novel genetic pathways involved in complex traits. PLoS One 6: e22070.
63. Bolotin E, Armendariz A, Kim K, Heo SJ, Boffelli D, et al. (2014) Statin-induced changes in gene expression in EBV-transformed and native B-cells. Hum Mol Genet 23: 1202-1210.
64. Sanders AR, Goring HH, Duan J, Drigalenko EI, Moy W, et al. (2013) Transcriptome study of differential expression in schizophrenia. Hum Mol Genet 22: 5001-5014.
65. Squassina A, Costa M, Congiu D, Manchia M, Angius A, et al. (2013) Insulinlike growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol Res 73: 1-7.
66. Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, et al. (2011) Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12: 171-184.
67. Morag A, Oved K, Gurwitz D (2013) Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs. J Mol Neurosci 49: 554-558.
68. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-2738. (Pubitemid 38263654)
69. Pieper K, Grimbacher B, Eibel H (2013) B-cell biology and development. J Allergy Clin Immunol 131: 959-971.
70. Rogge L, D'Ambrosio D, Biffi M, Penna G, Minetti LJ, et al. (1998) The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 161: 6567-6574. (Pubitemid 28562196)
71. Abramovich C, Chebath J, Revel M (1994) The human interferon alphareceptor protein confers differential responses to human interferon-beta versus interferon-alpha subtypes in mouse and hamster cell transfectants. Cytokine 6: 414-424. (Pubitemid 24263887)
72. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H (2013) Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 13: 443-451.
73. Fowler T, Sen R, Roy AL (2011) Regulation of primary response genes. Mol Cell 44: 348-360.
74. Pone EJ, Zan H, Zhang J, Al-Qahtani A, Xu Z, et al. (2010) Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit Rev Immunol 30: 1-29.
75. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, et al. (2013) Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14: 327-336.
76. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, et al. (2011) TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472: 361-365.
77. Versteeg GA, Rajsbaum R, Sanchez-Aparicio MT, Maestre AM, Valdiviezo J, et al. (2013) The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity 38: 384-398.